Association of Disease-Modifying Treatment With Outcome in Patients With Relapsing Multiple Sclerosis and Isolated MRI Activity.

Bsteh G, Aicher ML, Walde JF, Krajnc N, Haider L, Traxler G, Gradl C, Salmen A, Riedl K, Poskaite P, Leyendecker P, Altmann P, Auer M, Berek K, Di Pauli F, Kornek B, Leutmezer F, Rommer PS, Zulehner G, Zrzavy T, Deisenhammer F, Chan A, Berger T, Hoepner R, Hammer H, Hegen H. Neurology. 2024 Sep 24;103(6):e209752. doi: 10.1212/WNL.0000000000209752. Epub 2024 Aug 28. PMID: 39197111.

Switching from natalizumab to antiCD20 monoclonal antibodies: Short transition interval is associated with improved outcome.

Bsteh G, Hoepner R, Gernert JA, Berek K, Gradl C, Kliushnikova D, Damulina A, Traxler G, Föttinger F, Habernig S, Krajnc N, Betancourt AXL, Ponleitner M, Zrzavy T, Deisenhammer F, Di Pauli F, Havla J, Khalil M, Kümpfel T, Wipfler P, Chan A, Berger T, Hammer H, Hegen H. Eur J Neurol. 2025 Jan;32(1):e16587. doi: 10.1111/ene.16587. PMID: 39686558; PMCID: PMC11649819.

The Austrian MS Database and the Austrian MS Cohort – a national effort towards data harmonization and prospective data collection

Bsteh G, Föttinger F, Ponleitner M, Berek K, Di Pauli F, Deisenhammer F, Enzinger C, Berger T, Khalil M, and Hegen H, for the Austrian Multiple Sclerosis Database and Austrian MS cohort study group